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Introduction
Patients undergoing regular haemodialysis (HD) are at risk of complications associated with elevated serum phosphate levels which increasingly stimulate parathyroid gland production of parathyroid hormone (PTH) and proliferation and lead to accelerated bone resorption. 1 Hyperphosphataemia and hypercalcaemia also increase the calcium-phosphate product, potentiating metastatic calcification in soft tissues. 2 In addition, patients with elevated serum phosphate experience higher mortality and those with serum phosphate levels above 2.1mmol/l have a significantly increased risk of dying during their first year of treatment.
3
Standard thrice weekly HD is unable effectively to remove excess phosphate from the blood 4 and, therefore, patients need to restrict their dietary intake of food rich in phosphate and to take oral phosphate binders to control both serum phosphate and PTH levels. 5 Traditionally, patients are taught about the importance of both their diet and medication at the start of regular haemodialysis and this is reinforced as treatment continues. A number of studies have evaluated the efficacy of such teaching. 6, 7, 8, 9 Although some were unable to show a clinical benefit from teaching, 7,8 others reported that higher levels of knowledge about diet and medication and receiving education from a dietitian were associated with lower serum phosphate levels. 6, 9 However, in spite of these interventions, hyperphosphataemia remains a problem for a substantial number of HD patients 10 and there is a need to investigate standardised and reproducible protocols to facilitate the management of hyperphosphataemia. To this end, a phosphate management protocol was devised to enable renal dietitians and renal pharmacists to extend their traditional role in this area of practice under the auspices of a Patient Group Direction. 11 The aim of this study was to evaluate the effectiveness of the protocol, designed to optimise serum phosphate levels in patients undergoing regular haemodialysis.
Methods

Subjects
The subjects were recruited from adult outpatients with chronic renal failure undergoing regular excluded. Before entry into the study, serum phosphate levels were monitored for 4 months and patients with at least one value >1.8mmol/l during this period were invited to participate in the study. A total of thirty-four patients fitted the study criteria, agreed to participate and provided informed written consent. They were randomised into one of two study groups using a computer generated random number list:
i. Phosphate management protocol (PMP) group
ii.
Standard practice (SP) group
At recruitment, the two groups were comparable in terms of age, sex, ethnic group, aetiology of kidney disease, length of time since commencing regular haemodialysis and body mass index (BMI) ( Table 1 ). All study patients were reviewed and blood results monitored once per month for the 4-month duration of the study. At each monthly visit, all patients were seen individually by a renal dietitian who devised an individual care plan. The individual dietary advice was given after taking a diet history 12 and comprised verbal advice supported by either a detailed low phosphate diet booklet providing a comprehensive list of high-phosphate foods to avoid and suitable alternatives, or a simplified handwritten diet action plan. The choice of written material was based on each patient's circumstances and their perceived ability to understand the instructions given. Patients were advised whilst they were undergoing dialysis.
Phosphate management protocol group
In the PMP group, phosphate binder and alfacalcidol (vitamin D analogue) medication was adjusted using a specially designed phosphate management protocol. This was developed by the multi-disciplinary renal research team which included a renal consultant, dietitian and pharmacists. The protocol comprised two algorithms (Figure 1 ) that allowed the renal research pharmacists and renal research dietitian, working together, to change patients' medication as specified within the protocol without close supervision of a renal consultant. The protocol was approved by the BLT Patient Group Direction Committee. 11 The algorithms were used to inform changes to the dose and type of phosphate binder and the dose of alfacalcidol required to improve patients' serum phosphate, calcium and intact parathyroid hormone (iPTH) levels. Once per month, whilst the patients were undergoing dialysis, the renal research pharmacists explained the changes to their medication, counselled them about when to take them and adjustments in relation to the size of their meals, and provided a medication card. Once per month, the patients were also seen by the renal research dietitian.
Standard practice group
In the SP group, a senior doctor within the renal team reviewed the monthly blood results and the dose and type of phosphate binder and alfacalcidol during dialysis ward rounds or at an outpatient clinic. Once per month, the patients were also seen by a renal dietitian but were not seen by a pharmacist.
Monitoring
Routine blood samples were taken before dialysis within the first week of every month; serum was separated and frozen within 1 hour of blood collection. Serum phosphate and calcium concentrations were analysed using ultraviolet and colour photometric tests respectively 13, 14 and calcium-phosphate product (Ca x P) was calculated. Serum calcium concentrations were adjusted with reference to serum albumin (corrected calcium (mmol/l) = measured calcium (mmol/l) + ([40 -albumin (g/l)] x 0.02). Serum iPTH and aluminium concentrations were measured at the beginning and end of the study by an automated chemiluminescent immunoassay and atomic absorption spectrophotometry respectively. 15, 16 Adequacy of haemodialysis was assessed by single-pool Kt/V calculated at recruitment and at the end of the study. 17 Weight was recorded at the end of each dialysis session and using previously recorded height, BMI was calculated.
Statistical analysis
Power calculations indicated that a sample size of 17 patients in each group was required to detect a 15% reduction in serum phosphate levels (80% power at a significance level of 0.05) based on data from BLT haemodialysis patients in 2000. The distribution of variables was tested for normality using the Shapiro-Wilks' test (SAS 8.2, 2001, SAS Institute Inc, Cary, USA).
At baseline, comparisons were made between the two patient groups using unpaired t tests for normally distributed data, (most biochemical / nutritional variables, age) and Mann Whitney U tests for data not normally distributed (iPTH, time on dialysis). The difference between the baseline and post-intervention results within each group were compared using paired t-tests and the Wilcoxon matched pairs test. The difference between the change from baseline to postintervention in the two groups was evaluated using unpaired t tests and Mann Whitney U tests.
Categorical data were compared using the chi-squared test (male to female ratio) The study protocol was approved by North East London Strategic Health Authority (NELSHA)
Research Ethics Committee, reference number P/01/092.
Results
Forty-two patients were recruited into the study and randomised to one of the two intervention groups; 34 of these received the interventions (Figure 2 ). Three patients did not complete the study and all of these were allocated to the PMP group; two were withdrawn in week 6 after developing complicated or confounding medical conditions (total parathyroidectomy for severe hyperparathyroidism and oropharyngeal squamous cell carcinoma requiring feeding via a gastrostomy) and the third died from septicaemia secondary to endocarditis in week 9. The data from these patients were included in the comparative analysis at recruitment (Table 1) No statistically significant difference was observed in serum phosphate concentrations, corrected calcium, Ca x P or iPTH between the two groups at the start of the study (Table 2) . However, after the study, a significant increase in serum phosphate was observed in the SP group whilst the PMP group showed a small, insignificant reduction. A comparison between the two groups over the study period showed a significantly greater improvement in serum phosphate levels in the PMP group compared to the patients receiving standard practice (-0.22 ± 0.67 vs 0.19 ± 0.32 mmol/l, P=0.03). Parallel differences in the change in Ca x P product were observed between the two groups but there were no significant differences in the change in serum corrected calcium or iPTH levels ( Table 2) .
The proportion of patients achieving the K/DOQI target for serum phosphate increased in the PMP but decreased in the SP group following the intervention period but the changes were not significant within groups (Table 3) or between groups (data not shown). Similarly, the proportion of patients meeting multiple K/DOQI targets increased in the PMP and decreased in the SP group but again these trends were not significant (Table 4) .
Significantly more changes to the dose of individual phosphate binders were made in the PMP Eight breaches of the study protocol occurred during the study relating to physicians changing binders between monthly reviews without reference to the protocol. On each occasion, when the breach was identified by the pharmacist, the blood levels were reviewed promptly against the protocol and an appropriate amendment made in compliance with the protocol.
Discussion
The results from the current study show that use of a defined phosphate management protocol can 32 It has been speculated that by utilising a combination of phosphate binders in a systematic manner, the protocol might also reduce the risks associated with individual binders. 22 A large prospective study would be required to address this.
The total staff time required to deliver the phosphate management protocol compared with the standard treatment was not measured. Although, anecdotally no additional medical staff time was required with the PMP group, additional pharmacist and dietetic time was required. It could be argued that the additional staff time, rather than the protocol per se contributed to improved phosphate control. Future studies are needed to evaluate this and to explore the health economic implications of the protocol with regard to both staff time and prescribing costs.
The limitations of the study include the small number of patients studied. Although a statistically significant difference in the change of phosphate levels has been observed between the two groups, this small change is unlikely to have clinical significance. However, this could be explored in a future study by repeating the study in patients with more poorly controlled serum phosphate rather than in a population with a single serum phosphate level above 1.8mmol/l. It would be beneficial to also measure the residual renal function of patients, which was not done in the present study, in order to clarify their ability to control their serum phosphate. In future studies, the additional measurement of nutrient intake would allow the effect of dietary advice on phosphate intake to be directly evaluated as well as facilitating the examination of overall nutrient intake adequacy.
This study has shown that patients undergoing regular haemodialysis had significantly better serum phosphate control whilst managed with a protocol incorporating patient education, dietary counselling and pharmacotherapy than patients receiving standard management. A larger study is required to confirm whether the observed effects can be extended to other dialysis populations.
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